Eli Lilly Secures Approval for Alzheimer's Drug Kisunla in Japan
WEB2 days ago · Eli Lilly and Company price | Eli Lilly and Company Quote LLY Zacks Rank. Eli Lilly currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks ...
Eli Lilly's Alzheimer's drug approved in Japan | Reuters
WEB2 days ago · Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020. REUTERS/Mike Blake/File Photo Purchase Licensing Rights, opens new tab
Lilly hits record high after Mounjaro fuels forecast raise, rival data
WEBAug 8, 2023 · Eli Lilly on Tuesday raised its annual forecasts as demand for new diabetes drug Mounjaro surges ahead of a decision on its use as a weight-loss treatment, with shares soaring 18% to a record...
Lilly.com | Eli Lilly and Company
WEBINDIANAPOLIS , Sept. 9, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the appointment of Lucas Montarce as executive vice president and chief financial officer (CFO) and member of the company's …
Lilly's Kisunla™ (donanemab-azbt) Approved in Japan for the …
WEB3 days ago · "Lilly scientists have been dedicated to research in Alzheimer's disease for more than 35 years, and this news is testament to their ingenuity, perseverance, and commitment to helping people with this disease," said Ilya Yuffa, executive vice president and president of Lilly International, Eli Lilly and Company.
All News - Eli Lilly and Company
WEBLilly's latest press releases, stories, news resources and more.
News Release - Eli Lilly and Company
WEBMay 13, 2022 · FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes. May 13, 2022. PDF Version. Mounjaro delivered superior A1C reductions versus all comparators in phase 3 SURPASS clinical trials.
News Release - Eli Lilly and Company
WEBJul 14, 2023 · INDIANAPOLIS and NEW YORK, July 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Versanis Bio today announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases.
FDA approves weight loss drug from Eli Lilly that helped ... - NBC News
WEBNov 8, 2023 · The Food and Drug Administration on Wednesday approved Zepbound, a new weight loss drug from drugmaker Eli Lilly that was shown in clinical trials to help people lose up to 52 pounds in 16 months.
Alzheimer's drug donanemab shows positive results, Eli Lilly ... - CNBC
WEBJul 17, 2023 · Eli Lilly is racing to market donanemab for Alzheimer's after Eisai and Biogen's drug for the disease, Leqembi, won FDA approval this month.